Kong Garheng 4

4 · Xeris Biopharma Holdings, Inc. · Filed Jun 5, 2026

AI-generated summary of this filing

Updated Jun 5, 2026

Xeris (XERS) Director Kong Garheng Receives Stock Awards

What Happened

Director Kong Garheng received equity awards from Xeris Biopharma on June 4, 2026: 24,193 restricted stock units (RSUs) granted (acquired at $0) and 32,996 derivative securities reported as stock options with an exercise price of $6.15 (total shown as $202,925). These are grants/awards, not open-market purchases or sales.

Key Details

Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (no late filing indicated).
Grants: 24,193 RSUs (value reported as $0 on grant); 32,996 options at $6.15 exercise ($202,925 shown).
Vesting: Both awards vest in full upon the earlier of June 4, 2026 or the Company’s next annual meeting of stockholders, subject to continued service (see footnotes F1 and F2).
Shares owned after transaction: Not specified in the filing.
Transaction codes: A = Award/Grant; derivative code notes these are stock options (not exercised or sold).

Context

RSUs represent a contingent right to receive one share per unit upon vesting; they are not immediate cash purchases or sales.
The derivative entry reflects option grants (strike $6.15). This report does not show exercises, sales, or cashless transactions — only the grant of awards.
Grants to directors are common and often part of compensation; they are informational rather than definitive signals of personal trading intent.

Form 4

Period: 2026-06-04

Director

Transactions

Award
Common Stock
[F1]
2026-06-04+24,193→ 238,337 total
Award
Stock Option (Right to Buy)
[F2]
2026-06-04$6.15/sh+32,996$202,925→ 32,996 total
Exercise: $6.15Exp: 2036-06-04→ Common Stock (32,996 underlying)

Footnotes (2)

[F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
[F2]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Signature

/s/ Beth Hecht, Attorney-in-Fact|2026-06-05

1 file